Neurocrine Biosciences Inc. (NBIX) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Neurocrine Biosciences’s revenue went from $15M in fiscal 2016 to $2.9B in fiscal 2025, growth of about 79.2% a year.
Net income in fiscal 2025 was $479M, a net margin of 16.7%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $3.7B and net income $702M.
Free cash flow was $749M in fiscal 2025 and positive in 8 of the 10 years shown.
The diluted share count rose 18% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.7B | $2.9B | $2.4B | $1.9B | $1.5B | $1.1B | $1.0B | $788M | $451M | $162M | $15M |
| Gross profit | — | $2.8B | $2.3B | $1.8B | $1.5B | $1.1B | $1.0B | — | $446M | $160M | $15M |
| Operating income | $887M | $619M | $570M | $251M | $249M | $102M | $163M | $72M | $37M | -$131M | -$147M |
| Net income | $702M | $479M | $341M | $250M | $154M | $90M | $407M | $37M | $21M | -$143M | -$141M |
| EPS (diluted) | $6.74 | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | $-1.62 | $-1.63 |
| R&D | $1.2B | $1.0B | $731M | $565M | $464M | $328M | $275M | — | $161M | $122M | $94M |
| Revenue growth | — | +21.4% | +24.8% | +26.8% | +31.3% | +8.4% | +32.7% | +74.7% | +179.2% | +977.5% | −24.1% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.1B | $783M | $595M | $390M | $339M | $256M | $228M | $147M | $101M | -$94M | -$106M |
| Capital spending | -$26M | -$34M | -$38M | -$28M | -$16M | -$23M | -$11M | -$15M | -$25M | -$7M | -$4M |
| Free cash flow | $1.0B | $749M | $557M | $362M | $323M | $233M | $218M | $132M | $77M | -$101M | -$110M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $158M | $168M | $300M | $0 | $0 | — | — | — | — | — | — |
| Stock-based pay | $235M | $218M | $196M | $194M | $173M | $134M | $100M | $75M | $58M | $43M | $28M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $1.5B | $1.1B | $1.0B | $989M | $711M | $801M | $670M | $651M | $516M | $83M |
| Debt | — | $471M | $496M | $290M | $111M | $457M | $423M | $95M | $388M | $370M | $0 |
| Equity | — | $3.3B | $2.6B | $2.2B | $1.7B | $1.4B | $1.1B | $637M | $481M | $372M | $315M |
| Total assets | — | $4.6B | $3.7B | $3.3B | $2.4B | $2.1B | $1.7B | $1.3B | $993M | $818M | $365M |
| Shares (diluted) | 105M | 102M | 104M | 101M | 99M | 98M | 98M | 96M | 95M | 88M | 87M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 98.2% | 98.6% | 97.9% | 98.4% | 98.7% | 99.0% | — | 98.9% | 99.2% | 100.0% |
| Operating margin | 24.0% | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% |
| Net margin | 19.0% | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | 38.9% | 4.7% | 4.7% | -88.2% | -940.6% |
| FCF margin | 28.1% | 26.2% | 23.7% | 19.2% | 21.7% | 20.6% | 20.8% | 16.8% | 17.0% | -62.7% | -735.3% |
| ROIC | — | 11.3% | 13.0% | 7.5% | 9.9% | 5.0% | 8.3% | 7.9% | 4.1% | -17.7% | -46.8% |
| ROE | — | 14.7% | 13.2% | 11.2% | 9.0% | 6.5% | 36.2% | 5.8% | 4.4% | -38.3% | -44.8% |
Frequently asked questions
What is Neurocrine Biosciences’s annual revenue?
$2.9B in fiscal 2025 and $3.7B over the twelve months to September 30, 2026.
How much profit does Neurocrine Biosciences make?
Net income was $479M in fiscal 2025 (net margin 16.7%).
Is Neurocrine Biosciences’s revenue growing?
Yes: revenue rose 21.4% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.